D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia

Haematologica

Volumn 92, Issue 11, 2007, Pages 1565-1568

  Stam, Ronald W ^a   Den Boer, Monique L ^a   Schneider, Pauline ^a   Meier, Marrit ^a   Beverloo, H Berna ^b   Pieters, Rob ^a,c  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c INTERFANT 99 Collaborative Study Group

Author keywords

D HPLC; FLT3; Hyperdiploid ALL; MLL rearrangements; Mutation

Indexed keywords

CD135 ANTIGEN; MIXED LINEAGE LEUKEMIA PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DIPLOIDY; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC DISORDER; GENETIC SCREENING; HUMAN; INFANT; WILD TYPE;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA MUTATIONAL ANALYSIS; FMS-LIKE TYROSINE KINASE 3; GENE REARRANGEMENT; HUMANS; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PLOIDIES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 36348965968     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11220     Document Type: Article

References (24)

1. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100:1532-42.
2. Stone RM, De Angelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105:54-60.
3. Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103:3669-76.
4. O'Farrell AM, Yuen HA, Smolich B, Hannah AL, Louie SG, Hong W, et al. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res 2004;28:679-89.
5. Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, et al. Phase IB study of PKC412, an oral FLT3 inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (pts) with acute myeloid leukemia (AML) under age 61. In: American Society of Hematology (ASH) conference; 2006; Orlando, Florida, USA; 2006. Abstract #157.
6. Heidel F, Mirea FK, Breitenbuecher F, Dove S, Huber C, Bohmer FD, et al. Bis(1H-indol-2yl)methasones are effective inhibitors of mutated FLT3 tyrosine kinase, overcome resistance to PKC412A in vitro and show synergy with chemotherapy. In: American Society of Hematology (ASH) conference; 2006; Orlando, Florida, USA; 2006. Abstract #1369.
7. Taketani T, Taki T, Sugita K, Furuichi Y, Ishii E, Hanada R, et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequendy found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 2004;103:1085-8.
8. Brown P, Levis M, Shurtleff S, Campana D, Downing J, Small D. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of ELT3 expression. Blood 2005;105:812-20.
9. Armstrong SA, Mabon ME, Silverman LB, Li A, Gribben JG, Fox EA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004;103:3544-6.
10. Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB, et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 2005;106:2484-90.
11. Xu F, Taki T, Eguchi M, Kamada N, Ishii E, Endo M, et al. Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia. Japan Infant Leukemia Study Group. Leukemia 2000;14:945-7.
12. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002;30:41-7.
13. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002;1:133-43.
14. Jiang J, Paez JG, Lee JC, Bo R, Stone RM, De Angelo DJ, et al. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood 2004;104:1855-8.
15. Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E, et al. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AMI). Blood 2005;105:335-40.
16. Schittenhelm MM, Yee KW, Tyner JW, McGreevey L, Haley AD, Town A, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia 2006;20:2008-14.
17. Bianchini M, Ottaviani E, Grafone T, Giannini B, Soverini S, Terragna C, et al. Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC. Clin Chem 2003;49:1642-50.
18. Yu K, Herr AB, Waksman G, Ornitz DM. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc Natl Acad Sci USA 2000;97:14536-41.
19. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103:3222-5.
20. Forbes LV, Gale RE, Pizzey A, Pouwels K, Nathwani A, Linch DC. An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia. Oncogene 2002;21:5981-9.
21. Raffioni S, Zhu YZ, Bradshaw RA, Thompson LM. Effect of transmembrane and kinase domain mutations on fibroblast growth factor receptor 3 chimera signaling in PC12 cells. A model for the control of receptor tyrosine kinase activation. J Biol Chem 1998;273:35250-9.
22. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML, et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003; 3:173-83.
23. Griffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 2004;13:169-78.
24. Rosnet O, Marchetto S, deLapeyriere O, Birnbaum D. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene 1991; 6:1641-50.